Business
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
— Dr. Binks joins Capricor in anticipation of potential approval of deramiocel in Q3 2025, bringing extensive experience in neuromuscular and rare diseases —SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading glo
About this update from Capricor Therapeutics, Inc.
[{"type":"image","alt":"Capricor Therapeutics","displaySize":"","headline":null,"caption":"Capricor Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YaI1GjtfVRH2kLVsjMQa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7","width":300,"height":107}},"lazy":false},{"type":"text","content":"— Dr. Binks joins Capricor in anticipation of potential approval of deramiocel in Q3 2025, bringing extensive experience in neuromuscular and rare diseases —","length":157,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors.","length":447,"tagName":"p"},{"type":"text","content":"“Michael is an outstanding addition to Capricor’s leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities,” said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. “With over a decade of leadership in the DMD space, Dr. Binks is uniquely positioned to guide the medical and commercial advancement of our deramiocel program and help shape the next phase of our pipeline. This is a pivotal time to strengthen our medical leadership, and we are excited about the expertise and strategic vision he brings to the organization.”","length":656,"tagName":"p"},{"type":"text","content":"Dr. Binks is a board-certified rheumatologist (UK) and an internationally recognized expert in immunology and rare diseases. He previously held senior leadership roles at Pfizer and GlaxoSmithKline, where he played a key role in advancing several first-in-class therapies—including Benlysta, Hympavzi, Paxlovid, and Beqvez as well as multiple gene therapy, small molecule, and biologics programs across early...